Submitted by Anonymous (not verified) on 9 November 2023 - 12:43
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 18, Status: Authorised
Source: